[email protected]s.com +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Vitiligo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 124 pages | ID: VB278115509AEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Vitiligo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Drugs In Development, 2022, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 2, 1, 2, 15 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vitiligo - Overview
Vitiligo - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vitiligo - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vitiligo - Companies Involved in Therapeutics Development
Vitiligo - Drug Profiles
Vitiligo - Dormant Projects
Vitiligo - Discontinued Products
Vitiligo - Product Development Milestones
Featured News & Press Releases
Jul 19, 2022: US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment
May 10, 2022: Clinuvel progresses vitiligo study
May 09, 2022: CLINUVEL progresses vitiligo treatment program
Mar 26, 2022: Incyte announces 52-week data from the phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
Mar 18, 2022: Incyte announces multiple abstracts from its dermatology portfolio have been accepted for presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
Mar 14, 2022: Incyte announces U.S. FDA has extended the supplemental New Drug Application review period for ruxolitinib cream (Opzelura) for the treatment of vitiligo
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Dec 20, 2021: SCENESSE as vitiligo monotherapy
Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo
Oct 28, 2021: Incyte announces the validation of the European Marketing authorization application for Ruxolitinib Cream in Vitiligo
Oct 02, 2021: Incyte announces full results from phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
Sep 13, 2021: Incyte announces ruxolitinib cream data accepted for presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
May 18, 2021: Incyte’s ruxolitinib meets endpoints in Phase III trials for vitiligo
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Vitiligo, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Vitiligo - Pipeline by 2A Pharma AB, 2022
Vitiligo - Pipeline by AbbVie Inc, 2022
Vitiligo - Pipeline by Ahammune Biosciences Pvt Ltd, 2022
Vitiligo - Pipeline by Alexion Pharmaceuticals Inc, 2022
Vitiligo - Pipeline by Almirall SA, 2022
Vitiligo - Pipeline by Amgen Inc, 2022
Vitiligo - Pipeline by AnaptysBio Inc, 2022
Vitiligo - Pipeline by AnTolRx Inc, 2022
Vitiligo - Pipeline by APIRx Pharmaceuticals USA LLC, 2022
Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, 2022
Vitiligo - Pipeline by Avotres Inc, 2022
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Vitiligo - Pipeline by Elixiron Immunotherapeutics Inc, 2022
Vitiligo - Pipeline by Forte Biosciences Inc, 2022
Vitiligo - Pipeline by HysensBio Corp, 2022
Vitiligo - Pipeline by Incyte Corp, 2022
Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Vitiligo - Pipeline by JN Biosciences LLC, 2022
Vitiligo - Pipeline by Pfizer Inc, 2022
Vitiligo - Pipeline by Radikal Therapeutics Inc, 2022
Vitiligo - Pipeline by Rhizen Pharmaceuticals SA, 2022
Vitiligo - Pipeline by Shanghai Icure Biotechnology Co Ltd, 2022
Vitiligo - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Vitiligo - Pipeline by TagCyx Biotechnologies, 2022
Vitiligo - Pipeline by Technoderma Medicines Inc, 2022
Vitiligo - Pipeline by Temprian Therapeutics Inc, 2022
Vitiligo - Pipeline by TWi Biotechnology Inc, 2022
Vitiligo - Pipeline by Villaris Therapeutics Inc, 2022
Vitiligo - Pipeline by VYNE Therapeutics Inc, 2022
Vitiligo - Dormant Projects, 2022
Vitiligo - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Vitiligo, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications